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Cardiotoxicity is a relatively frequent and potentially 
serious complication of oncology treatment. Anthracy-
clines with their acute, chronic and late cardiotoxicity 
represent the greatest risk [1]. Various methods have 
been recommended for monitoring of cardiotoxicity 
in oncology [2, 3]. In our conditions, echocardiography 
(ECHO) and electrocardiography (ECG) are routinely 
used [4, 5].
ECG is among recommended diagnostic methods 
for detection of cardiotoxicity in oncology. It is a widely 
available and low-cost examination. ECG changes 
were registered in 11–29% patients during and shortly 
after anthracycline administration, but the incidence 
strongly depends on the frequency of monitoring. 
In some studies, acute ECG changes and arrhythmias 
were registered in up to 41% patients treated by anthra-
cyclines [2]. The ECG changes associated with anthra-
cyclines include non-specific changes in ST segment 
and T wave, sinus tachycardia, supraventricular and 
ventricular premature beats. These changes are usu-
ally transient and no relation to development of chronic 
cardiotoxicity was proven. Continuous 24-hour moni-
toring of ECG (Holter) may reveal arrhythmias both 
in early and late periods of anthracycline treatment [6]. 
Furthermore, QRS voltage lowering in the limb leads 
was reported during progression of anthracycline-
induced cardiomyopathy with heart failure [7]. After 
anthracycline-based treatment, QTc interval prolon-
gation and increased QTc dispersion were reported 
[8–10] which generally represent a risk for malignant 
ventricular arrhythmias and sudden cardiac death. 
Some prior studies suggested that QTc interval pro-
longation after anthracycline administration could 
be an early marker of left ventricular (LV) dysfunction 
[9]. In other studies, however, QTc prolongation was 
only transient and no correlation with LV dysfunction 
on ECHO examination was found [11]. 
The aim of the presented study was to monitor ECG 
changes during and after anthracycline treatment and 
to compare these changes with findings on ECHO 
examination.
A total of 26 patients with newly diagnosed acute 
leukemia were included in the study. The cohort con-
sisted of 15 males and 11 females with the mean age 
of 46.2 ± 12.4 years (range: 22–61, median 49). The 
patients were treated with 2–6 cycles of chemotherapy 
(CT) containing anthracycline agents (idarubicin, 
daunorubicin or mitoxantrone) in combination with 
cytarabine. The mean total cumulative dose of anthra-
cyclines reached 464.3 ± 117.5 mg/m2 (range 240–
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715, median 429). Myeloablative preparative regimen 
followed by hematopoietic cell transplantation was 
subsequently administered in 16 patients. The study 
was approved by the local ethical committee and all 
patients gave a written consent before they were in-
cluded in the study.
In all patients, resting 12-lead ECG records with 
a paper speed of 50 mm/s were performed at the base-
line (before CT), after the first CT with anthracyclines 
(after first CT, mean cumulative anthracycline dose 
136.3 ± 28.3 mg/m2), after the last CT with anthracyclines 
(after last CT, mean 464.3 ± 117.5 mg/m2) and circa 
6 months after completion of the treatment (6 months 
after CT). Evaluated ECG parameters were as follows: 
time parameters (heart rate, RR interval, PQ interval, QRS 
duration, QT interval), voltage parameters (total QRS 
voltage in the limb leads) and presence of repolarization 
changes, arrhythmias or other abnormalities. The ECG 
measurements were performed manually by 2 indepen-
dent physicians who were blinded to clinical data. A total 
of 104 ECG records were evaluated. 
To obtain heart-rate corrected values for QT in-
terval (QTc interval), we used the Bazett’s formula: 
QTc = QT / √RR [12]. The upper limits of normal for 
QTc interval duration using the Bazett’s formula were 
suggested 420 ms for males and 430 ms for females. 
According to the latest guidelines of the National Can-
cer Institute (NCI) — Common Terminology Criteria for 
Adverse Events v3.0 (CTCAE), QTc interval prolonga-
tion above 450 ms in connection with oncology treat-
ment is regarded as cardiac adverse event [13]. In our 
study, the QTc interval above 450 ms was considered 
significantly prolonged and representing a risk factor 
for development of ventricular arrhythmias. Decreases 
in the total QRS voltage in the limb leads (measured 
in leads I, II, III, aVR, aVL, aVF) by > 1.0 mV versus 
baseline values were considered significant.
ECHO examinations were performed on Hewlett 
Packard Image Point ultrasound at the same time 
as ECG records. Parameters of systolic and diastolic left 
ventricular (LV) function were assessed. Systolic LV dys-
function was defined as ejection fraction (LVEF) ≤ 55%. 
Diastolic LV dysfunction was defined as E/A inversion 
and E-wave deceleration time above 220 ms on the 
transmitral Doppler curve (impaired relaxation). 
Statistical analysis was performed with the “Sta-
tistica for Windows, Version 5.0” program. Analysis 
of variance and McNemar tests were used. Correla-
tions were evaluated with normal and Spearman cor-
relation tests. The values are expressed as mean ± SD, 
p < 0.01 was considered statistically significant.
ECG abnormalities in connection with anthracy-
cline treatment are shown in Table. During treatment 
and follow-up, we found a statistical significant QTc 
interval prolongation — 414.7 ± 16.0 ms (before CT), 
419.6 ± 21.6 ms (after first CT), 428.0 ± 16.2 ms (after 
last CT) and 430.1 ± 18.4 ms (6 months after CT). After 
last CT and 6 months after CT, QTc interval prolonged 
significantly in comparison with the baseline value 
(p < 0.01). After first CT, no patient had QTc interval 
prolongation above 450 ms. After first CT, QTc interval 
prolonged above 450 ms in 3 (11.5%) patients, after 
last CT in 4 (15.4%) patients, and 6 months after 
CT in 5 (19.2%) patients. 
Table. Occurrence of ECG abnormalities in connection with anthracycline 
chemotherapy for acute leukemia (n = 26)
ECG abnormalities Before CT After first CT
After last 
CT
6 months 
after CT
Tachycardia 4 3 0 3
Bradycardia 1 3 1 1 
First degree AV block 0 1 5 2
iRBBB 1 2 3 3
LAH 0 1 2 3
Repolarization abnormalities 5 8 11 12
QTc prolongation 0 (6) 3 (8) 4 (16) 5 (15)
QRS voltage lowering – 3 5 6
Notes: tachycardia — heart rate above 100/min; bradycardia — heart rate 
below 60/min; first degree AV block — PQ interval above 200 ms; iRBBB 
(incomplete right bundle branch block) — RSR̓ pattern in V1 (V2), QRS 
duration below 120 ms; LAH (left anterior hemiblock) — left axis deviation, 
heart axis below –30°; nonspecific repolarization abnormalities — changes 
in ST segment and T wave in 2 and more leads; QTc prolongation — QTc 
interval above 450 ms regardless gender (above 420 ms in males, above 
430 ms in females); QRS voltage lowering — decrease in the total QRS 
voltage in the limb leads > 1.0 mV vs baseline values.
The total QRS voltage in the limb leads changed from 
baseline 4.58 ± 1.31 mV (before CT) to 4.57 ± 1.55 mV 
(after first CT), 4.42 ± 1.15mV (after last CT) and 
4.22 ± 1.06 mV (6 months after CT). In comparison with 
the baseline values, QRS voltage decreased signifi-
cantly in 3 (11.5%) patients after first CT, in 5 (19.2%) 
patients after last CT and in 6 (23.1%) patients within 
6 months after CT. 
Repolarization abnormalities associated with on-
cology treatment (de novo changes or distinct progres-
sion of the baseline changes) were found in 9 (34.6%) 
patients within 6 months after CT.
On ECHO examination, we found systolic LV dys-
function in 1 (3.8%) patients after first CT, in 3 (11.5%) 
patients after last CT and in 5 (19.2%) patients within 
6 months after CT. Diastolic LV dysfunction on ECHO 
was detected in 5 (19.2%) patients after first CT, 
in 6 (23.1%) patients after last CT and in 12 (46.2%) 
patients within 6 months after CT.
We found significant correlations between QRS vol-
tage lowering and LV dysfunction on ECHO (r = 0.660, 
p < 0.001 for systolic LV dysfunction; r = 0.592, p < 0.01 
for diastolic LV dysfunction). Correlations between 
prolonged QTc interval and LV dysfunction on ECHO 
also reached statistical significance (r = 0.246, p < 0.01 
for systolic LV dysfunction; r = 0.257, p < 0.01 for dia-
stolic LV dysfunction). 
Our results show that anthracycline-based treat-
ment for acute leukemia causes changes in electrical 
activity of the myocardium, both during the treat-
ment (acute cardiotoxicity) and during the follow-
up (chronic cardiotoxicity). QTc interval prolongation 
above 450 ms, in our cohort in 5 (19.2%) patients 
within 6 months after CT, represents a risk factor for 
development of malignant ventricular arrhythmias (tor-
sade de pointes) and sudden cardiac death. In these 
patients, regular monitoring of QTc interval is neces-
sary, complemented with searching for electrolyte dis-
orders (especially hypokalemia and hypomagnesemia, 
e. g. in case of vomiting or diarrhea) with potential 
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correction, and rational prescription of QTc interval 
prolonging drugs (many antiarrhythmics, tricyclic 
antidepressants, antipsychotics, some antibiotics and 
antifungal drugs etc.) [14, 15]. In our cohort, malignant 
ventricular arrhythmias did not occur during the follow-
up in any of the patients with significantly prolonged 
QTc interval. 
In our study, decreased total QRS voltage in the 
limb leads and prolonged QTc interval on ECG correla-
ted with systolic and diastolic LV dysfunction on ECHO. 
Further studies on a larger number of patients will 
be needed to prove whether these ECG changes could 
serve as an accessible and non-invasive screening 
method indicating LV dysfunction after anthracycline 
treatment.
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